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Abstract
Background: The prevalence of depressive disorder in adults with advanced cancer is around 20 %. Although
cognitive behavioural therapy (CBT) is recommended for depression and may be beneficial in depressed people
with cancer, its use for depression in those with advanced disease for whom cure is not likely has not been
explored.
Methods: People aged 18 years and above with advanced cancer attending General Practitioner (GP), oncology
or hospice outpatients from centres across England will be screened to establish a DSM-IV diagnosis of
depression. Self-referral is also accepted. Eligible consenters will be randomised to a single blind, multicentre,
randomised controlled trial of the addition to treatment as usual (TAU) of up to 12 one-hour weekly sessions
of manualised CBT versus TAU alone. Sessions are delivered in primary care through Increasing Access to
Psychological Care (IAPT) service, and the manual includes a focus on issues for people approaching the end
of life. The main outcome is the Beck Depression Inventory-II (BDI-II). Subsidiary measures include the Patient Health
Questionnaire, quality of life measure EQ-5D, Satisfaction with care, Eastern Cooperative Oncology Group-Performance
Status and a modified Client Service Receipt Inventory. At 90 % power, we require 240 participants to enter the trial.
Data will be analysed using multi-level (hierarchical) models for data collected at baseline, 6, 12, 18 and 24 weeks. Cost
effectiveness analysis will incorporate costs related to the intervention to compare overall healthcare costs and QALYs
between the treatment arms. We will conduct qualitative interviews after final follow-up on patient and therapist
perspectives of the therapy.
Discussion: This trial will provide data on the clinical and cost effectiveness of CBT for people with advanced
cancer and depression. We shall gain an understanding of the feasibility of delivering care to this group through
IAPT. Our findings will provide evidence for policy-makers, commissioners and clinicians in cancer and palliative
care, and in the community.
Trial registration: Controlled Trials ISRCTN07622709, registered 15 July 2011.
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Background
Depression is one of the most prevalent mental disorders
in people with cancer [1]. It undermines the quality of life
for individuals and those close to them [2], may reduce
adherence to medication, and may prolong episodes of
hospitalisation and increase healthcare costs [3]. Un-
treated depression is an independent predictor of early
death in those with advanced cancer [4].
The prevalence of depression in people with cancer is
around 10 % [5] and in advanced cancer may be as high as
21 % [6]. It is possible to treat depression effectively in the
general population using antidepressant medication and
psychological treatments such as cognitive behavioural
therapy (CBT) and interpersonal therapies [7, 8]. However,
it is not known whether these approaches are beneficial in
those people with cancer who experience depression or
those whose low mood exceeds what might be expected in
the face of life-limiting illness. A recent systematic review
of randomized controlled trials of the efficacy of any treat-
ment intended to reduce depression in adults with diagno-
ses of both cancer and depression found that only seven
relatively small trials have been published [9].
A meta-analysis in 2008 [10] suggested that CBT may
be a promising approach [11], although a recent sys-
tematic review of interventions for depression in can-
cer, patients of which are a poor prognostic group, did
not generate any well-designed trials where a CBT
intervention was used [9]. Indeed, all currently pub-
lished trials in this field having methodological limita-
tions [10, 12, 13]. The use of specially trained nurses to
use CBT skills in palliative care has not been shown to
alleviate depressive symptoms in cancer [14]. Whilst
some benefit may exist for nurse-led problem solving
therapy and behavioural activation for depression in ad-
vanced cancer [9], the effectiveness of CBT remains to
be evaluated. Evidence exists from qualitative studies
with people receiving hospice care that CBT is accept-
able [15], but no studies have explored the therapists’
experience of delivering CBT in this context.
The overall economic cost of depression in England was
estimated at £9 billion in 2000 [16]. The costs associated
with providing standard therapy through IAPT for depres-
sion and anxiety is estimated at £750 per patient [17]. Esti-
mated savings are around £1,200 in the first 2 years for
the additional GDP produced per person as a conse-
quence of treatment and £300 in NHS costs. The costs at-
tributed to a reduction in suffering, which are measured
by the change in quality-adjusted life years, is estimated at
£3,300 [17]. Choosing a value of a unit reduction on the
BDI-II of greater than £115 as acceptable, CBT is likely to
be cost-effective for treating depression in older people in
the UK [18]. In a recent UK RCT, the economic evaluation
of CBT as an adjunct to care as usual showed that the
intervention was cost-effective over 12 months, based on
the threshold of £20,000 per QALY used by the National
Institute for Health and Care Excellence [19].
A review of the cost-effectiveness of CBT could not
draw firm conclusions from the limited data available
[20]. Although economic evidence did provide tentative
support for the hypothesis that CBT was more efficient
than usual care and suggested a modest cost-effective
advantage in favour of CBT, none of the reviewed RCTs
were in advanced cancer cohorts.
In this paper, we describe the protocol for a national,
single-blind, two-arm, randomised controlled trial of up
to 12 sessions of CBT offered in addition to usual care
through the UK Improving Access to Psychological
Therapies (IAPT) service available through primary care,
versus usual care alone, for people with advanced cancer
who have a DSM-IV diagnosis of depression. We include
a nested qualitative component to explore, after final
follow-up, the experience of therapy from the perspec-
tives of both participants and therapists. Our data will
increase our understanding of the feasibility of delivering
this service through IAPT in primary care. Our trial was
funded in response to a call from the UK National Insti-
tute for Clinical and Care Excellence (NICE) to assess the
clinical and cost effectiveness of CBT for depression in
this context. Our results will also inform policy-makers
advising the London Cancer Alliance and IAPT itself on
the suitability of using IAPT for treating those facing can-
cer long-term or in the advanced stages.
A favourable opinion for the conduct of the study was
granted by the London-Camberwell St. Giles NRES com-
mittee, Central London REC3 ref 11/LO/0376. This study
forms part of the National Cancer Research Network
(NCRN) clinical trials portfolio registration number 10255,
ISTCRN number 07622709.
Hypothesis and Objectives
Hypothesis
Cognitive Behaviour Therapy plus treatment as usual is
more clinically and cost effective than treatment as usual
for major depression in adults with cancer that is no lon-
ger amenable to curative treatment.
Objectives
The objectives of this study are as follows:
1) To determine through a randomised controlled trial
the clinical effectiveness of Cognitive Behaviour
Therapy plus treatment as usual compared to
treatment as usual for depression in adults with
cancer which is no longer amenable to curative
treatment.
2) To determine through a randomised controlled trial
the cost effectiveness of Cognitive Behavioural
Therapy plus treatment as usual compared to
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treatment as usual for depression in adults with
cancer which is no longer amenable to curative
treatment.
Methods/design
Study design
This is a parallel group, single blind, randomised con-
trolled trial comparing treatment as usual (TAU) against
TAU plus up to 12 sessions of manualised cognitive be-
havioural therapy (CBT).
Population
The study population includes people aged ≥ 18 years
with cancer that is no longer amenable to cure, who also
have a DSM-IV diagnosis of major depression.
Location
Recruitment will take place in several sites across England
from a variety of clinical services situated in oncology out-
patient clinics, primary care clinics or hospices.
Oncology outpatient services where recruitment will
take place include those available in 18 hospitals covered
by cancer networks in North Central, North East and
South East London as well as in the Midlands, West,
North East, North West and the South of England. Pri-
mary care recruitment will take place through General
Practitioner (GP) cancer/palliative care registers through
the National Institute of Health Research (NIHR) Pri-
mary Care Research Network (PCRN). Participating
practices are drawn from the PCRN in areas in which
co-applicants are based and where IAPT services are
well established and available across the UK. Finally we
will also recruit through Marie Curie Hospice Hamp-
stead’s outpatients and day care services.
Entry criteria for participation in the trial
Inclusion criteria are as follows:
1. People with a diagnosis of cancer not amenable to
curative treatment as assessed by their clinician and
defined as those receiving palliative radiotherapy,
chemotherapy, those with metastatic disease, or
subsequent incurable recurrence. This diagnosis will
be verified by oncologists or GPs.
2. A DSM-IV diagnosis of depressive disorder using
the Mini International Neuropsychiatric Interview
(MINI) [21].
3. Sufficient understanding of English, judged by clinic
staff, to be able to engage in CBT.
4. Eligible for treatment in an IAPTcentre. Either the
patient or their GP must be located in an appropriate
IAPT catchment area.
Exclusion criteria are:
1. Clinician estimated survival of less than 4 months,
verified by the patients’ oncologists or GPs.
2. People with high suicide risk, established through
module C of the MINI. The care pathway is
described below under risk management.
3. Currently receiving or having received, in the last
2 months, a psychological intervention
recommended by NICE aimed at treating depression
(for example, Interpersonal Psychotherapy, CBT).
4. Suspected alcohol dependence using the Alcohol
Use Disorders Identification Test (AUDIT; [22]).
5. To avoid contamination of the TAU arm by non-
study CBT, we will not recruit in areas where the local
palliative care service includes routine access to CBT.
Risk management
When a patient is identified to be at high suicide risk dur-
ing screening, a clear protocol is in place in which the
patient’s key worker is notified and further assessment
sought through the regular team. The researcher remains
with the patient until additional help is available.
Participant randomisation
Participants will be randomised to one of two condi-
tions: treatment as usual (TAU) or treatment as usual
plus CBT. Randomisation will occur after patients have
been assessed to meet the eligibility criteria, have con-
sented to participate and baseline measures have been
collected. The trial administrator will send participant
details to PRIMENT Clinical Trials Unit (a UKCRC
registered CTU) where randomisation will occur using
Sealed Envelope, a web-based system. Antidepressants
are a predictor of outcome [23]. In cancer, tricyclic anti-
depressants may be preferentially prescribed over SSRIs
because they have fewer relevant side effects, such as
nausea, and may be used for both mood and, in lower
doses, for pain. Indeed even low doses of tricyclics may
be effective [24]. We will therefore stratify our random-
isation according to whether or not participants are in
receipt of an antidepressant, irrespective of dose.
Masking
Remaining blind to the treatment group will not be pos-
sible for patients or therapists. The researchers and
PCRN assessors will be blinded and will be asked to
guess group allocation (TAU alone, TAU plus CBT, do
not know) at 12 weeks (post-intervention) and 24 weeks
(follow-up). Unmasking for those conducting the ana-
lysis will not occur until the databases are closed.
Recruitment methods and procedures
From outpatient oncology clinics
NCRN support staff working with UCL researchers will
facilitate recruitment from oncology outpatient clinics.
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Patient GP addresses will be checked to determine that
they are eligible to be referred to an IAPT service before
they are approached. Either support staff or UCL re-
searchers will then screen suitable patients for depression
using the PHQ-2 [25, 26] which includes the first two
questions of the Patient Health Questionnaire (PHQ-9)
[27], a valid screening measure for depression routinely
used in general practice.
Patients who score 3 or more, will be provided with a
pre-screening information pack and asked if they would
be willing to be assessed for the study. If they score 3 or
more but do not wish to participate, their permission
will be sought for their GP or oncology team to be
informed that they may be depressed. If they agree in
principle to take part, a researcher will undertake a further
assessment, using the Mini International Neuropsychiatric
Interview (MINI) to establish a DSM IV diagnosis of de-
pressive disorder. Screening will be conducted in a place
and manner to maximise the privacy of the patient, in an
assessment room where this is possible, within the con-
straints of the clinical environment of each screening
centre.
If a DSM IV diagnosis of depression is confirmed, the
patient will be given an information pack. The patient will
then be given at least 48 hours to decide if they wish to
participate in the study before giving written consent for
participation. For those who consent to take part, the re-
searcher will then conduct baseline assessments and pass
the participant’s details to an independent trial administra-
tor, who will arrange randomisation through PRIMENT
Clinical Trials Unit. The study administrator will inform
the participant by telephone of their group allocation. For
those people randomised to the treatment arm, the ad-
ministrator will liaise with IAPT to set up the therapeutic
sessions. Both administrator and PRIMENT are situated
separately from the trial research team to maximise mask-
ing of trial arm allocation from the researchers.
From GP lists, the PCRN staff
The researcher and PCRN staff will liaise with practice
managers and ask them to identify people from their
databases who may be eligible for screening. By mutual
agreement according to availability at any practice, ei-
ther the PCRN staff or the researcher will then contact
people by telephone or face to face in practices to ex-
plore whether they are willing to answer the two PHQ
screening questions for depression. The PCRN staff
and/or researchers will then follow the same recruit-
ment procedure described above.
Self-referral
With the permission of clinical leads in each service,
posters and leaflets about the study will be placed in
approved oncology clinics and GP practices. The leaflet
contains the PHQ-2 for people themselves to conduct a
quick assessment of their mood, suggesting to people
with a score of 3 or more, that they may have depres-
sion and that they should either (a) approach the clin-
ical team within the site or (b) contact the study team
directly using the reply slip attached to the leaflet. The
process of recruitment will then be the same as that
outlined above.
Description of the Interventions
TAU
All participants will receive TAU from all clinicians in-
volved in their care. This consists of routine support
such as appointments with GPs, clinical nurse special-
ists, oncologists and palliative care clinicians. Partici-
pants’ physical health and medications will be reviewed
and treatment modified according to symptoms such as
pain. Psychotropic medication will be prescribed as ne-
cessary by either the GP or oncologist. In line with NICE
guidance, specific psychological support may be available
for those who present with psychological needs at any
time, and study participants will not be exempt from re-
ceiving external psychological support. We will discourage
specific psychological interventions aimed at treating
symptoms of depression (for example, CBT or Interper-
sonal Psychotherapy), but ultimately we cannot interfere
with usual care. We will record the numbers of people re-
ceiving any psychological therapy during the trial, al-
though the numbers are likely to be small [28].
In cancer, tricyclic antidepressants may be preferen-
tially prescribed over SSRIs because they may be helpful
in the management of pain and are less associated with
commonly experienced nausea and gastrointestinal
problems. Determining the therapeutic dose of anti-
depressant is complex and even low doses of tricyclic
antidepressants may be effective [24]. We cannot stipu-
late that post-randomisation anti-depressant medication
cannot be used or that the dose should be fixed. With-
holding a recognised treatment for depression would be
unethical and would not reflect treatment as usual.
Cognitive Behaviour Therapy (in addition to Treatment As
Usual)
The CBT will be delivered through ‘improving access to
psychological therapies’ (IAPT) and wellbeing centres.
IAPT/wellbeing centres train, supervise and supply ther-
apists to treat people in primary care with mental health
problems. For the purpose of the study, only step 3 and
step 4 (high intensity) therapists will be used. They will
be given a day’s training by the CanTalk team (SM, MS
and KM), so their existing CBT skills can be adapted to
use a specially developed treatment manual for people
with advanced cancer. The manual details modifications
in the structure of therapy and its content; in particular,
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it takes into account physical health problems, existen-
tial issues and communication with loved ones.
Structure of CBT sessions
NICE recommends 16 to 20 sessions of CBT to treat se-
vere depression in secondary care. Experience shows that
in primary care, considerably fewer sessions are taken up.
People with advanced cancer may have difficulty coping
with longer therapy as their health may be deteriorating.
Our intervention will consist of up to 12 sessions of indi-
vidual CBT delivered face to face or on the telephone over
3 months. Twice weekly sessions may be offered for the
first 2 weeks, weekly sessions for weeks 3 to 9 and then 2
sessions in weeks 10 to 12. The timing of the sessions will
need to be flexible and pragmatic to fit in with the existing
commitments of the IAPT service.
In order to facilitate engagement for those who may
not be able to attend sessions face to face, telephone
CBT may be offered, providing at least three sessions of
face-to-face therapy have already been received. Tele-
phone CBT is already used by IAPT therapists. Moorey,
Serfaty, and Mannix will teach CBT therapists how to
adapt their CBT techniques for telephone counselling
using similar methods to Tutty et al. [29].
Content of CBT sessions, guided by a written manual
IAPT guidelines recommend that patients with moderate
to severe depression and complex needs receive high in-
tensity (step 3) work. This is consistent with the level 4
psychological interventions recommended by NICE [30]
for people with cancer. The CBT intervention will use a
flexible approach, adapted for use with people with ad-
vanced illness, who face a poor prognosis. The manual
was developed by Moorey, Mannix and Serfaty, in which
therapists adapted their work to patients with advanced
cancer. The key shift is to identifying whether thinking
and behaviour are ‘helpful’ or ‘unhelpful’ rather than a
reality-testing approach, enabling patients to adopt adap-
tive strategies to cope with adverse and often unpredict-
able health circumstances.
The intervention will broadly cover the following:
In session 1, an assessment of problems, psychoeduca-
tion about depressive disorder and an introduction to the
cognitive model will be undertaken. A simple cross-
sectional formulation of current emotional distress will be
established, and the triggers to emotional distress and
how to manage them will be identified, with steps towards
one of the patient’s goals. A list of enjoyable activities will
be instigated, and unhelpful thinking styles will be identi-
fied using specific examples from recent events. Session 2
will aim to help patients develop an understanding of their
problems within a cognitive behavioural framework and
begin the process of therapy, using cross-sectional formu-
lation. This will include a discussion of past strengths and
coping abilities. Behavioural activation techniques will be
used within the constraints of the person’s physical illness.
Session 3 will review the formulation, identifying any new
insights/changes. Guided discovery, through a deeper
discussion of the patient’s thoughts/beliefs around their
illness and their resilience, will help them to apply their
resilience under current circumstances. A start will be
made on identifying ‘helpful’ versus ‘unhelpful’ thinking
and behaviours. Sessions 4 to 5 will help the patient apply
new learning to current difficulties, recent success experi-
ences will be reformulated, and helpful changes will be
identified. Guided discovery will be used to help the per-
son notice successful experiences and build resilience. The
triggers to emotional distress and strategies for responding
will be explored. These will include thought testing
and in-session experimentation with allowing intrusive
thoughts to pass. Session 6-7 will focus on thought
testing and finding ‘helpful’ alternative thoughts. This
will be done within sessions, supplemented by home-
work completed by the patient between sessions,
where logs of patient mood and associated thoughts
and behaviours are reviewed. Thoughts and behaviours
will then be challenged, and more helpful alternatives
considered. Examples of recent success experiences
will be added to successes lists and exploration of
these for their associated ‘helpful’ thoughts.’ Session 8
will focus on problem solving and worry time. Con-
firmation will be made that thought testing/‘helpful’
thoughts concept has been understood. Examples of
realistic concerns will be identified to generate a ‘prob-
lems to address’ list. An example of one problem will
be taken to illustrate the problem-solving approach.
The concept of ‘worry time’ will be introduced. Session
9 will consolidate CBT strategies, reviewing and priori-
tising a problem list. Planning on how to tackle harder
problems will be undertaken, identifying unhelpful
thoughts and behaviours with consideration of the pros
and cons of potential solutions and the commitment to
this process. A review of the use of worry management
strategies will also be done. Session 10 will consist of a
review of the person’s perceived progress, including
successes and difficulties. Session 11 will consist of re-
lapse prevention. This will include reviewing present-
ing difficulties, the progress and personal achievement
made, personal resilience and successes, and the devel-
opment of a relapse prevention checklist. Session 12
will consist of future planning, reviewing a relapse-
prevention checklist, making concrete plans for action
if emotional distress recurs or unhelpful behaviours/
thinking return. In addition, therapists will be taught on
materials contained in three sections in the Manual’s ap-
pendix, so, if relevant, these may be addressed with partic-
ipants. These will include, first, covering existential issues
in addition to addressing fears about the mode of dying,
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fears about the effect of death on others, and fears
about what happens after death; second, applying CBT
in shorter sessions when health is poor, how to deal
with fatigue and coping with loss of function; and third,
facilitating communication with partner, families and
carers. This will include identifying differing assumptions
about attitudes to cancer and illness-related behaviour.
In addition telephone CBT will be implemented. Re-
cent evidence suggests that the use of telephone CBT in
the treatment of depression is both clinically and cost
effective [30, 31]. We will therefore use this approach
where necessary with people who may not be able to
continue to attend face-to-face CBT sessions. We antici-
pate that this situation may arise for some people whose
physical condition deteriorates as their cancer progresses.
This will improve engagement and minimise attrition.
Therapist experience and characteristics
All therapists who work on this trial will be high-intensity
therapists. They will have completed a postgraduate dip-
loma in CBT and will have at least 2 years clinical experi-
ence post-CBT qualification. These high-intensity IAPT
therapists will be familiar with using either cognitive be-
haviour therapy according to Beck’s model [32] and/or the
Seattle Behavioural Activation Programme. Our therapy
will use a modified Beck’s model.
Additional training for therapists to deliver CBT for patients
with advanced cancer
As therapists may not be familiar with the complex needs
and existential issues of people with advanced cancer, they
will be trained to adapt their skills.
Therapists working on the trial will be required to at-
tend a 1-day training programme on how to apply CBT in
this context. A number of the components have already
been used for training other healthcare professionals to
deliver CBT in advanced cancer or palliative care [14].
Quality control: adherence to treatment and evaluation of
therapy
Therapists will record the components of the therapy
that they provide to individual participants using a simi-
lar checklist piloted in a previous study [28] but adapted
for people with cancer (Table 1). We will encourage all
therapists to upload recordings of therapy where pos-
sible onto a secure data base using encryption software.
Local healthcare trust policy and therapists’ experience
of IT systems may limit this process. We will aim to
sample 1 in 10 audio recordings of therapy sessions and
sample recordings depending on the phase of the inter-
vention (early: sessions 1 to 4, mid: sessions 5 to 8, or
late: sessions 9 to 12). Selected sessions will be rated by
an accredited member of the British Association of Be-
havioural and Cognitive Psychotherapists using Revised
Cognitive Therapy Scale (CTS-R) [33], which is a reliable
measure of the delivery of CBT [34].
Therapist supervision and workload
Weekly supervision is a prerequisite of practice within
IAPT services and audio-recordings of all therapy ses-
sions is routinely made. Although supervision structures
are well set up within IAPT services, SM, KM and MS
will be available to discuss any difficulties related to in-
terventions in people with cancer. We anticipate that
two IAPT therapists will be required from each Primary
Care Trust (PCT) to treat approximately 4.5 participants
per year each. We have experience in delivering a train-
ing programme for palliative care nurses in CBT skills
[35], which improves confidence in managing patients
[36]. Relevant sections of this have been adapted to pro-
vide CBT therapists with confidence in adapting their
skills to people with advanced cancer.
Measures
Screening measures
PHQ – 2: The PHQ-2 [25] consists of the first two
questions of the Patient Health Questionnaire (PHQ-9;
[27]) a valid screening measure of depression has also
been used in cancer services.
The Mini-International Neuropsychiatric Interview
(M.I.N.I.) is a short structured diagnostic interview,
which takes 15 minutes to complete. It was developed
jointly by psychiatrists and clinicians in the United
States and Europe for DSM-IV and ICD-10 psychiatric
disorders [21] and has been widely used in cancer
patients.
Outcome measures
We will collect a number of measures at different time
points as shown in Table 2 below.
Primary outcome
Beck Depression Inventory-II (BDI-II; [37].
This is a 21-item self-report measure with a maximum
score of 63 indicating severe depressive symptoms. It
contains few items measuring affective-somatic symp-
toms, with 15 of the 21 items assessing negative cogni-
tions, which are a target of cognitive interventions. The
psychometric properties of the BDI-II are similar to the
BDI [38], which is the most widely used self-report in-
strument for depressive symptoms and has also been
used in trials of psychotherapy for people with advanced
cancer [13, 39, 40]. The BDI-II also has a number of
cognitive elements that are particularly useful for meas-
uring change with CBT.
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Table 1 Therapy component checklist
Session the component was covered: 1 2 3 4 5 6 7 8 9 10 11 12
General procedures
Initial assessment
Describe Beck’s model and concept of cognitive behavioural therapy (CBT)
Agree on goals of therapy
Present a shared formulation
Goal setting
Review of shared formulation
Review of success list
Relapse prevention/future planning
Behavioural techniques
Relaxation training
Breathing space
Activity schedule
Pleasure experiences sheet
Cognitive techniques
Refocusing techniques
Mindfulness
4-Step process for resilience and coping
Coping map
List of strengths and resources
Reattribution
De-catastrophizing
Advantages/disadvantages
Success list
Thought diary
Personal rule (pros/cons)
Managing worry (worry tree handout)
Blueprint for coping
Cognitive-behavioural Techniques
Guided discovery
Pleasure prediction sheet
Pleasure experiences sheet
Negative triad/negative automatic thoughts
Applying resilience
Thinking traps handout
Reality testing
Searching for alternatives
ABC form
Specific cancer topics
Impact of physical illness
Beliefs and expectations about illness
Plans and hopes for care as disease advances
Relationship between emotions and physical symptoms
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Secondary outcomes
Patient Health Questionnaire
The Patient Health Questionnaire (PHQ9) [27] screens
for depression. It is used in primary care settings, includ-
ing IAPT services. It has been validated as a measure of
depression in primary care [41, 42] and can be adminis-
tered over the telephone [43].
EuroQol
The EuroQol (EQ5D) [44, 45] is a generic utility measure
of quality of life consisting of five domains and a visual
analogue scale. It will be used in the cost-effectiveness
analysis.
Satisfaction with care
Satisfaction with care is collected using a visual analogue
scale (scored 0 to 10 towards higher satisfaction). This
method was used in previous psychotherapy research [46].
Eastern Cooperative Oncology Group-Performance Status
The Eastern Cooperative Oncology Group-Performance
Status (ECOG-PS) [47] is a scale measuring physical func-
tioning on five levels: 0, asymptomatic normal activity; 1,
symptomatic but fully ambulatory; 2, symptomatic and in
bed less than 50 % of time; 3, symptomatic and in bed
more than 50 % of time; 4, 100 % restricted to bed.
Measure of service utilisation
Client Service Receipt Inventory
The Client Service Receipt Inventory (CSRI) is a short
modified version of the CSRI [48], which collects data
directly from participants on use of hospital services,
day centres, residential homes, rehabilitation centres,
paramedic/ambulance, community nurses, occupational/
physio therapists, and local GP/practice nurses, as well
as social care/social housing use.
Measures to reduce bias
At baseline
Antidepressant use Use of antidepressants may predict
outcome and is likely to be correlated with health-
services use, such as visits to GP, affecting costs per pa-
tient in cost-effectiveness evaluation. We shall record
the name and dose of any antidepressants prescribed to
participants during the course of the study, as well as
any changes in prescribing patterns.
Table 1 Therapy component checklist (Continued)
Concerns about current and future ability to cope
Concerns about loss of control
Concerns about accepting help
Concerns about dying (mode/afterwards/life expectancy)
Impact of disease and mood on behaviour
Impact of disease/death on loved ones
Discussion of ‘the meaning’ of the illness
Acceptance of unfinished business
Table 2 Outcome measures and timepoints
Measures T3 Baseline T4 (6 weeks)
Mid-intervention
T5 (12 weeks)
Post-intervention
T6 (18 weeks)
Follow-up
T7 (24 weeks)
Follow-up
PHQ-9 ✓ ✓ ✓
BDI-II ✓ ✓ ✓ ✓ ✓
EQ5-D ✓ ✓ ✓
Satisfaction with care ✓
ECOG-PS ✓ ✓ ✓
CSRI ✓ ✓ ✓
Antidepressant ✓ ✓ ✓
Expectation of therapy ✓
Blindness ✓ ✓
Attrition ✓ ✓
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Other psychological therapies We will make a record
of any psychological intervention reported by patients or
recorded in their case notes during the period of the
trial.
(iii) Expectations at baseline [49]. Prior to randomization,
participants will be asked to predict the degree to which
they think their mood will improve or not on a seven-
point Likert scale ranging from -3 to +3.
Treatment preference Patients’ preferences for treat-
ment will be collected on a four-point Likert scale (0-3)
as in Serfaty et al. [28].
Post-intervention (12 weeks post-baseline)
Non-attendance for CBT
Reason for not attending therapy sessions (for example,
did not like therapy, recorded death, etcetera).
Patient satisfaction
We shall ask participants to rate on a five-point scale
(ranging from not at all to very much) whether they
found CBT useful.
At follow-up (24 weeks post-baseline)
Assessment of blindness
Each researcher undertaking assessments will be asked
to guess the patient’s trial arm (CBT plus TAU, TAU, do
not know).
Attrition
Reason for missing follow-up data (for example, too ill,
died, etcetera).
Statistical analysis
Sample size and power calculations
Published data for trials of CBT suggest that initial reduc-
tions in BDI-II with time may not be linear. A separation
in depression scores favouring therapy is observed within
6 weeks of starting treatment [50, 51] and continues after
the treatment phase has finished [52, 53].
For ethical reasons, participants are entitled to withdraw
from the study without giving a reason; however, we will
record the reason for withdrawal from the trial if known.
We shall record the timing of any attrition. Differential
dropout may occur early on because people are not satis-
fied with their trial arm allocation. Drop out at later
phases is more likely to be due to factors such as death,
which are less likely to be influenced by group allocation.
Details of the assumptions made are described below and
summarised on Table 3.
Power
(i) Clinical effectiveness: Our primary outcome is an over-
all effect of treatment over the 24-week period of follow-
up. We have powered the study to enable detection of a
difference in BDI-II of six points (standard deviation 12)
between the TAU and CBT groups measured at 12 weeks,
assuming a treatment effect of three points after 6 weeks,
and a sustained six-point difference after 18 and 24 weeks
(Table 1). We have been cautious in assuming a sustained
rather than an increasing treatment effect after 12 weeks.
Follow-up at 12 weeks post-baseline in other trials ranges
from 44 % [14] to over 75 % [12, 13]. Although our client
group may be in the last year of life, we do not plan to re-
cruit people who are about to die. We will assume a 70 %
follow-up rate after 6 weeks, decreasing to 65 % at
12 weeks and 60 % after 24 weeks (Table 3).
The BDI-II manual reports that the correlation be-
tween BDI-II values from sessions 1 week apart is 0.93
(Beck and Steer [37]). To estimate the correlation be-
tween measurements 6 weeks apart, the simplest as-
sumption possible is that future values will depend only
on the most recent past, and not on any history prior to
that (in technical terms, this is called an ‘autoregressive
process of order 1’). Then, the correlation between mea-
surements will decay at a constant rate of 0.93 per week,
and our best estimate of the correlation between BDI-II
measures taken 6 weeks apart is 0.936 = 0.65.
Assuming the attrition rates and correlation reported
above, the sample size required to detect an overall differ-
ence between the groups, at 90 % power and 5 % signifi-
cance is 109 participants per trial arm (using a multi-level
model adjusting for baseline BDI-II). To account for clus-
tering by therapist, the sample size needs to be inflated by
a factor of 1.10. (1 + (average cluster size -1) × intra-class
correlation coefficient). This is based on an intra-class cor-
relation coefficient of 0.02 [54, 55] and an average of six par-
ticipants per therapist post-intervention. We therefore
intend to recruit 120 participants per trial arm, with the ex-
pected numbers available at each follow-up given in Table 1.
An important secondary outcome is to assess how the
treatment effect changes over time.
Table 3 Assumptions made about numbers of participants at
different timepoints
Time Cognitive
behavioural
therapy over
treatment as
usual;
difference in
BDI-II score
Percent
remaining
in the
study
TAU CBT
n = 120 n = 120
0 weeks (baseline) 0 100 120 120
6 weeks 3 70 84 84
12 weeks 6 65 78 78
18 weeks 6 63 76 76
24 weeks 6 60 72 72
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The proposed sample size will provide 90 % power to
detect a six-point difference in BDI-II at 12 weeks and
80 % power to detect a six-point difference at 24 weeks
if attrition rates are as stated in Table 3.
Analysis plan
Clinical data: Analysis of data will be undertaken accord-
ing to CONSORT guidelines within PRIMENT Clinical
Trials Unit. A flow chart will present the follow-up rate
for each group, with the reason for non-completion of
the BDI-II score. Descriptive results (mean and SD) for
demographic and pre and post-treatment BDI-II scores
at each follow-up period will be presented by treatment
group. Analyses will be on an intention-to-treat basis
using multi-level (hierarchical) models. The levels of
hierarchy in the data are as follows: first level - repeated
measures, second level - participants, and third level -
therapist. The primary analysis will test for an overall
treatment effect on an intention-to-treat basis using
BDI-II over the four follow-ups, controlling for baseline
BDI-II score and other baseline confounders, including
antidepressant dose. A secondary analysis will also look at
the effect of treatment separately at each time point, by in-
cluding a treatment-time interaction in the multi-level
model. A complier average causal effect (CACE) analysis
will be performed to take into account the possible lack of
adherence to CBT. Analyses will be performed using the
current version of STATA (version 13) [56].
Antidepressants will be monitored in order to compare
their use between groups to check that they are similar.
This will be done by recording all antidepressants pre-
scribed during the trial (name, dose and frequency). This
will include SSRIs and other antidepressants such as tricy-
clics, which are often used in small doses for symptom
control in end-of-life care. We will convert antidepressant
dose for any drug into a mean equivalent dose of imipra-
mine following a method we used in another trial of CBT
for depressed older people [28].
Analysis of economic data
Resource use and costs: Our trial population will have
serious physical illness, with multiple hospital contacts
for necessary physical treatments recommended by cli-
nicians. It is therefore unlikely that hospital utilisation
for physical reasons will differ significantly between the
two arms, and this is therefore not being recorded to
minimise patient burden. We will, however, record the
number of contacts with community services, including
mental health, especially as these are most likely to be
influenced by our intervention. Therefore, the CSRI will
be modified to collect data on community health ser-
vices only. Resource utilisation will be multiplied by
unit costs [57, 58] to estimate individual-level care-
package costs for each patient at baseline and over the
trial period. Costs related to the intervention will be in-
cluded. We will calculate mean cost of CBT per partici-
pant, the incremental health and social care cost, the
incremental QALY gain and incremental cost-effectiveness
ratio. Results will be analysed on an intention-to-treat
basis. Using multivariate regression methods, we will ex-
plore differences in costs and outcomes between treat-
ment groups. We shall adjust for need-related factors,
including functionality (assessed using BDI-II).
Bootstrapped incremental cost-effectiveness ratios and
acceptability curves will be estimated in order to relate
differences in costs and outcomes between the groups.
Capturing benefits over a patient’s lifetime is an import-
ant issue, given outcome data will be missing at the end
of the trial. We will use assumption-based modelling
techniques [58] to explore the cost-effectiveness of the
intervention using a lifetime horizon. In order to assess
the key thresholds at which the intervention would be
cost-effective, threshold analysis, for example, may be
used as one method of framing assumptions around
transition probabilities. The reliability of the model will
depend on the quality and extent of missing data from
the trial.
Qualitative data
We will use purposive sampling and write to 20 partici-
pants in the trial who received CBT at the end of their
follow-up period to invite them to take part in qualitative
interviews to explore their experience of the trial and their
therapy. We will also interview 12 therapists to explore
their experience of delivering therapy to this population.
Semi-structured, one-to-one interviews will be conducted
using a topic guide either in the participants’ homes or in
the department where the research is taking place. All
interviews will be audio recorded for transcription at a
later date. Data will be analysed using thematic content
analysis. Findings from these data will be used to generate
recommendations on what may be improved in the deliv-
ery of CBT to people with advanced cancer.
Ethical approval
This trial has been approved by the London-Camberwell
St. Giles Research Ethics Committee, part of the NHS
Health Research Authority (reference 11/LO/0376). The
trial will be conducted in compliance to the Declaration
of Helsinki. Informed written consent will be obtained
from all participants.
Discussion
This trial will provide robust evidence on the effectiveness
and cost-effectiveness of individual cognitive behaviour
therapy for treating people with advanced cancer and de-
pressive disorder. Cancer will affect one in three of the
UK population during their lifetime, and it remains one of
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the commonest causes of death. In caring for people with
advanced cancer, much effort may be expended on ad-
dressing treatments for physical problems including the
management of symptoms such as pain, nausea and
fatigue that are common as health deteriorates. Good
supportive care at this time should include accurate as-
sessments of mental health, and diagnosis and treatment
for depression when necessary. If found to be effective,
use of talking therapies may enhance the experience not
only of those people facing advanced cancer but also those
close to them.
This trial will generate data to aid our understanding
of the feasibility of delivering CBT to a population with
deteriorating physical health in the community through
the existing network of IAPT therapists. We shall gain
information on the interfaces between oncology services
in secondary care, CBT in primary care and the hospice
in the third sector. Some day care services provided
through hospices have the capacity to offer talking therap-
ies within current models of care [59, 60]. Evidence from
this trial may inform the likely benefits of strengthening
these services within palliative care, as well as assess
whether augmenting usual care with CBT is cost-effective
based on the National Institute for Health and Care Excel-
lence threshold.
Analyses of the content of therapy sessions will en-
hance our understanding of the issues of importance to
people with advanced cancer who experience depression.
Our data may reveal domains of worry and psychological
need in those facing the approach of death with which
we are not yet familiar. Such new knowledge may enable
the development of recommendations and guidance for
therapists providing CBT in this context, and for the
wider clinical community caring for people with cancer
for whom cure is not likely.
Trial status
Participant recruitment began on 19 September 2012 and
is ongoing.
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